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Reply to: The use of acoustic radiation force-based shear stiffness
in non-alcoholic fatty liver disease
To the Editor:
We appreciate the comments and clinical perspectives raised by
Dr. Cross in response to our recent publication concerning the use
of acoustic radiation force-based shear stiffness values in NAFLD
patients to evaluate ﬁbrosis scores [1], and we would like to take
this opportunity to respond to those points. Dr. Cross mentions
the signiﬁcant number of failed stiffness reconstructions in our
study (21.5%), which we agree would be too high for a screening
test to evaluate liver ﬁbrosis. It should be noted that the majority
of those reconstruction failures (84%) occurred in patients with
BMI >30. As discussed in the manuscript [1], higher BMI is
associated with deeper livers, reduced acoustic radiation force
magnitudes, and therefore noisier data for performing the
reconstructions. Many of these patients with failed shear wave
reconstructions did not meet our quality control threshold of
having an IQR/mean60.3 over the replicate shear wave estimates
in the three imaging locations. This reconstruction variability is
an active research efforts focused on improving the next genera-
tion of shear wave reconstruction algorithms. Additionally, we
would recommend restricting the imaging locations utilized in
patients with high BMI to help improve the repeatability of the
reconstructed stiffnesses. While the intercostal imaging windows
tended to yield repeatable shear wave reconstructions, the
addition of the subcostal window was associated with additional
variability in this subset of patients, most likely due to the addi-
tional subcutaneous fat at this location.
Although an intention-to-treat analysis was not performed in
the context of our study, one can argue that knowledge of the
absence of advanced NAFLD (i.e. ﬁbrosis stage 3–4) using a
non-invasive test would decrease resource utilization and cost
associated with performing liver biopsies in all patients with sus-
pected NAFLD. As highlighted in Fig. 2 of the referenced manu-
script [1], the shear modulus across the early stages (ﬁbrosis
stage 0–2) of disease is very narrow, and those patients do not
have increased morbidity or mortality from liver and cardiovas-
cular related outcomes. With the exception of optimizing risk
factors for disease progression, patients with early stage disease
do not require surveillance and monitoring for complications
associated with advanced hepatic ﬁbrosis. We agree with Dr.
Cross that additional statistical analyses are necessary to better
deﬁne the sensitivity, speciﬁcity, negative and positive predictive
values as well as positive and negative likelihood ratios for such a
non-invasive test to have widespread clinical applicability. How-
ever, such analyses would ideally include a much larger sample
size. Therefore, larger studies powered to derive meaningful
threshold values capable of guiding clinical decisions are
necessary.
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Transplanted hepatocytes: Wiped out or washed out?
studies have pointed to a small sub-population of biliary duct
cells, also being Sox9-positive, as being bipotential, driving
progenitor cell-mediated liver regeneration [3], seemingly giving
rise to Foxl1-expressing progenitor cells, also with bipotentiality,
but with limited proliferation potential [4]. A further murine
study has shown that 0.076% of all albumin-expressing hepato-
cytes are born from albumin-naïve cells every 4 days in normal
healthy mice, again highlighting the dynamic cell state of the
normal liver [5].
These murine studies have re-awakened the discussion as to
whether hepatocytes ‘stream’ from portal tracts to hepatic veins,
ﬁrst described for the rat liver [6]; subsequently with the liver
being formally proposed as a ‘stem cell and lineage system’, hier-
archically organized into stem, amplifying and differentiating
Letters to the EditorTo the Editor:
Hope for the long-term effectiveness of hepatocyte
transplantation (HTx) for metabolic liver disease in pediatric
patients is based on the premise that hepatocytes in the main
constitute a static population, quite unlike for example, the small
bowel where there is constant turnover. However, several recent
studies on the dynamics of hepatocyte turnover raise important
questions about the long-term success of HTx. For example, a
recent lineage tracing study in the mouse has demonstrated that,
within a year, almost the total parenchymal population is
replaced by new hepatocytes differentiating from Sox9-express-
ing interlobular bile ducts [1,2], suggesting that transplanted
hepatocytes will inevitably be ‘washed out’ of the liver within
the turnover time – in about 1 year in the mouse. Other murine996 Journal of Hepatology 2012 vol. 56 j 993–999
compartments [7]. Very recently, these cell maturational stages
have been characterized in great detail in terms of the likes of
morphology, ploidy, proliferation, biochemistry and gene expres-
sion [8]. Moreover, our own recent studies in the human liver,
demonstrating a portal tract to hepatic vein orientation of groups
of clonally-derived hepatocytes, are in line with the concept of a
dynamic lineage system [9]. On the other hand, not all studies
have concurred with this concept, for example Bralet and col-
leagues [10] genetically labeled rat hepatocytes in vivo at 24 h
after partial hepatectomy, but failed to observe any change in
their location (periportal and mid-zonal) over the proceeding
15 months – observations not consistent with a ‘streaming’
liver.
There are recent examples of the fairly long-term beneﬁcial
effects of HTx and survival of engrafted cells, for example, a
Crigler-Najjar patient survived well for 4 years after HTx before
an OLT and he still had conjugated bilirubin in his blood at
3.5 years [11]. In 2006, Sokal’s group performed a HTx for the
correction of argininosuccinate lyase deﬁciency, and cell track-
ing conﬁrmed their durable presence (12.5%) in the liver at
7 months after the last infusion [12]. More recent information
on that same case conﬁrmed that the patient was still doing
well at up to 18 months when she received an OLT [13]. On
the other hand, the majority of children undergoing HTx for
urea cycle disorders have only been monitored for a relatively
short time before OLT, though one 3-year-old patient with cit-
rullinemia was still doing well 30 months after HTx [14]. Many
other cases of HTx have also only provided short-term beneﬁt
including glycogen storage disease type I [15], and factor VII
deﬁciency [16].
In most studies, the absence of a sustained beneﬁt of HTx in
the medium to long-term has been ascribed to rejection
(‘wipe-out’) or other causes not directly related to HTx itself
(e.g. infections), but we would like to suggest that hepatocyte
egress (‘wash-out’) could be an alternative, but non-exclusive
explanation. We believe it is beholden upon hepatologists to once
and for all establish the cell replacement dynamics of the liver,
preferably in a large animal model. If the ‘streaming liver’
hypothesis wins the day then attempts at the correction of
metabolic liver disease should be directed towards targeting
cholangiocytes and/or other hepatocyte progenitors or only
transplanting hepatocytes into extrahepatic sites.
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Entecavir in the treatment of chronic hepatitis B
in kidney transplantation
To the Editor:
We have read with interest the review by Vallet-Pichard et al.
published in a recent issue of the Journal [1]. In the section ‘‘Recom-
mendation for HBV therapy’’ they reviewed the scarce data pub-
lished on this topic. They cited the article published by Kamar
et al. as the only experience with NUC therapy in renal transplan-
tation [2].We have published our experience with entecavir treat-
ment in a small population of chronic HBV patients with chronic
kidney disease [3]. Eleven male patients – 1 with stage 4 chronic
kidney disease, 7 undergoing hemodialysis in the waiting list for
a transplant, and 3 kidney transplanted recipients –were included
in the study evaluation. Six were treatment naïve, and 5 were
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